Diagnosed prevalent cases of cystic fibrosis are expected to increase considerably over the forecast period mainly due to improving survival.
By Niharika Dandamudi, Senior Epidemiologist
29 July 2016
I am a Senior Epidemiologist at Datamonitor Healthcare. I have a Master’s in Public Health from Birla Institute of Tec...
Read full bio
In 2015, Datamonitor Healthcare estimates that there were over 65,000 diagnosed prevalent cases of CF in the US, and five major EU (France, Germany, Italy, Spain and UK) markets which are expected to increase to over 100,000 cases by 2035 showing an absolute positive growth of 55.1%. Japan was excluded in this forecast considering very low frequency of CF in Asian populations including Japan (Yamashiro et al., 1996). The largest single proportion of diagnosed prevalent cases of CF was found in the US which comprised 46.4% of cases. Of the 5EU markets, the UK had the highest number of cases and Spain had the lowest number of cases. The increase in the CF diagnosed prevalent patient population over the forecast period can be attributed mainly to increasing survival rates due to various factors suggested in the literature. Additionally, age-specific, and clinically relevant patient segmentations (severity, lung infection by pathogens, mutations, complications) of diagnosed prevalent cases of CF are reported.
Datamonitor Healthcare’s Cystic Fibrosis: Epidemiology used proprietary epidemiologic methods combining country-specific registry data and supplemental epidemiology sources, where applicable, to estimate diagnosed prevalent cases of CF in the US, and five major EU markets (France, Germany, Italy, Spain, and the UK) between 2015 and 2035. Prevalent cases are segmented by severity, genetic mutation, pathogen infection, and complications.